N-3 polyunsaturated fatty acids may affect the course of COVID-19
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F60460709%3A41210%2F22%3A91358" target="_blank" >RIV/60460709:41210/22:91358 - isvavai.cz</a>
Result on the web
<a href="https://www.frontiersin.org/articles/10.3389/fimmu.2022.957518/full" target="_blank" >https://www.frontiersin.org/articles/10.3389/fimmu.2022.957518/full</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.3389/fimmu.2022.957518" target="_blank" >10.3389/fimmu.2022.957518</a>
Alternative languages
Result language
angličtina
Original language name
N-3 polyunsaturated fatty acids may affect the course of COVID-19
Original language description
The highly infectious coronavirus disease (COVID 19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS CoV 2), which is a new coronavirus that has been spreading since late 2019 and has caused millions of deaths worldwide. COVID 19 continues to spread rapidly worldwide despite high vaccination coverage therefore, it is crucial to focus on prevention. Most patients experience only mild symptoms of COVID 19. However, in some cases, serious complications can develop mainly due to an exaggerated immune response that is, a so called cytokine storm, which can lead to acute respiratory distress syndrome, organ failure, or, in the worst cases, death. N3 polyunsaturated fatty acids and their metabolites can modulate inflammatory responses, thus reducing the over release of cytokines. It has been hypothesized that supplementation of n3 polyunsaturated fatty acids could improve clinical outcomes in critically ill COVID 19 patients. Some clinical trials have shown that administering n3 polyuns
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30102 - Immunology
Result continuities
Project
Result was created during the realization of more than one project. More information in the Projects tab.
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)
Others
Publication year
2022
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Frontiers in Immunology
ISSN
1664-3224
e-ISSN
1664-3224
Volume of the periodical
13
Issue of the periodical within the volume
Sep
Country of publishing house
CH - SWITZERLAND
Number of pages
12
Pages from-to
1-12
UT code for WoS article
000868652200001
EID of the result in the Scopus database
2-s2.0-85139549317